Pegvisomant

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 634 publications

Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.

Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.

Journal: Pituitary

Published: May 29, 2026

Injection-Site Sarcomas in Rodent Carcinogenicity Studies: Human Relevance and Labeling Implications.

Injection-Site Sarcomas in Rodent Carcinogenicity Studies: Human Relevance and Labeling Implications.

Journal: Toxicologic pathology

Published: May 12, 2026

Genome architecture in endocrine diseases: X-Linked Acrogigantism (X-LAG) syndrome.

Genome architecture in endocrine diseases: X-Linked Acrogigantism (X-LAG) syndrome.

Journal: Annales d'endocrinologie

Published: May 08, 2026

Letter to the editor: Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

Letter to the editor: Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

Journal: Pituitary

Published: April 24, 2026

Genome architecture in endocrine diseases: X-linked acrogigantism (X-LAG) syndrome.

Genome architecture in endocrine diseases: X-linked acrogigantism (X-LAG) syndrome.

Journal: Annales d'endocrinologie

Published: March 26, 2026

Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities.

Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities.

Journal: JFMS open reports

Published: March 26, 2026

Growth hormone receptor antagonism improves tumoral chemo-immunotherapy response in a mouse model of lung cancer.

Growth hormone receptor antagonism improves tumoral chemo-immunotherapy response in a mouse model of lung cancer.

Journal: Translational oncology

Published: February 23, 2026

Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches.

Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches.

Journal: Drugs

Published: January 30, 2026

Current treatment landscape of acromegaly.

Current treatment landscape of acromegaly.

Journal: The Journal of clinical endocrinology and metabolism

Published: January 26, 2026

Approach to the patient: Precision Medicine-Guided Evaluation and Treatment of Acromegaly.

Approach to the patient: Precision Medicine-Guided Evaluation and Treatment of Acromegaly.

Journal: The Journal of clinical endocrinology and metabolism

Published: January 10, 2026

Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment.

Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment.

Journal: Journal of medical economics

Published: January 10, 2026

Comprehensive Pharmacovigilance Assessment of Pegvisomant-Associated Adverse Events Using the FDA Adverse Event Reporting Systemand World Health Organization VigiAccess Databases.

Comprehensive Pharmacovigilance Assessment of Pegvisomant-Associated Adverse Events Using the FDA Adverse Event Reporting Systemand World Health Organization VigiAccess Databases.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: January 03, 2026

Showing 1-12 of 634

Last Updated: 06/30/2026